Citations

Clear

2 citation(s) found for "Schroeder, Matthew K".

TOpCLASS Expert Consensus Classification of Perianal Fistulising Crohn’s Disease: A Real-world Application in a Serial Fistula MRI Cohort
Schroeder, Matthew , Abushamma, Suha , George, Alvin T , Ravella, Balakrishna , Hickman, John A. , Elumalai, Anusha, Ludwig, Daniel R. , Viswanath, Satish E. , Schroeder, Matthew K , Sebastian, Shaji , Ballard, David H , Deepak, Parakkal , Viswanath, Satish E , Hickman, John, Wise, Paul E. , Zulfiqar, Maria , Shetty, Anup S. , Luo, Chongliang , Ballard, David H. , Deepak, Parakkal

Mayo Clinic

Journal of Crohn's and Colitis | April 18, 2024 | Volume: 18 | Issue: 9 | Pages: 1430-1439

10.1093/ecco-jcc/jjae056 | PMID 38642332 Get It

Abstract Background and Aims Perianal fistuliing Crohn’s disease [PFCD] is an aggressive phenotype of Crohn’s disease defined by frequent relapses and disabling symptoms. A novel consensus classification system was recently outlined by the TOpCLASS consortium, which seeks to unify disease severity with patient-centred goals but has not yet been validated. We aimed to apply this to a real-world cohort and to identify factors that predict transition between classes over time. Methods We identified all patients with PFCD and at least one baseline and one follow-up pelvic MRI [pMRI]. TOpCLASS classification, disease characteristics, and imaging indices were collected retrospectively at time periods corresponding with respective MRIs. Results We identified 100 patients with PFCD, of whom 96 were assigned TOpCLASS Classes 1–2c at baseline. Most patients [78.1%] started in Class 2b, but changes in classification were observed in 52.1% of all patients. Male sex [72.0%, 46.6%, 40.0%, p = 0.03] and prior perianal surgery [52.0% vs 44.6% vs 40.0%, p = 0.02] were more frequently observed in those with improved class compared to unchanged and worsened class. Baseline pMRI indices were not associated with changes in classification; however, greater improvements in mVAI, MODIFI-CD, and PEMPAC were seen among those who improved. Linear mixed effect modelling identified only male sex [-0.31, 95% CI -0.60 to -0.02] with improvement in class. Conclusion The TOpCLASS classification highlights the dynamic nature of PFCD over time. However, our ability to predict transitions between classes remains limited and requires prospective assessment. Improvement in MRI index scores over time was associated with a transition to lower TOpCLASS classification.
HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial
Perez, Edith A. , Reinholz, Monica M., Tenner, Kathleen , Schroeder, Matthew, Davidson, Nancy E. , Martino, Silvana, Harris, Lyndsay N. , Dueck, Amylou C. , Ketterling, Rhett P. , Lingle, Wilma L., Visscher, Daniel W., Jenkins, Robert B. , Hillman, David W. , Sledge, George W. , Gralow, Julie R. , Ingle, James N. , Kaufman, Peter A. , Dueck, A. C. , Ketterling, Rhett P

Mayo Clinic

Journal of Clinical Oncology | August 10, 2010 | Volume: 28 | Issue: 28 | Pages: 4307-4315

10.1200/jco.2009.26.2154 | PMID 20697084 Get It

Purpose We examined associations between tumor characteristics (human epidermal growth factor receptor 2 [HER2] protein expression, HER2 gene and chromosome 17 copy number, hormone receptor status) and disease-free survival (DFS) of patients in the N9831 adjuvant trastuzumab trial. Patients and Methods All patients (N = 1,888) underwent chemotherapy with doxorubicin and cyclophosphamide, followed by weekly paclitaxel with or without concurrent trastuzumab. HER2 status was determined by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) at a central laboratory, Mayo Clinic, Rochester, MN. Patients with conflicting local positive HER2 expression results but normal central laboratory testing were included in the analyses (n = 103). Results Patients with HER2-positive tumors (IHC 3+, FISH HER2/centromere 17 ratio ≥ 2.0, or both) benefited from trastuzumab, with hazard ratios (HRs) of 0.46, 0.49, and 0.45, respectively (all P < .0001). Patients with HER2-amplified tumors with polysomic (p17) or normal (n17) chromosome 17 copy number also benefited from trastuzumab, with HRs of 0.52 and 0.37, respectively (P < .006). Patients who received chemotherapy alone and had HER2-amplified and p17 tumors had a longer DFS than those who had n17 (78% v 68%; P = .04), irrespective of hormone receptor status or tumor grade. Patients with HER2-normal tumors by central testing (n = 103) seemed to benefit from trastuzumab, but the difference was not statistically significant (HR, 0.51; P = .14). Patients with hormone receptor–positive or –negative tumors benefited from the addition of trastuzumab, with HRs of 0.42 (P = .005) and 0.60 (P = .0001), respectively. Conclusion These results confirm that IHC or FISH HER2 testing is appropriate for patient selection for adjuvant trastuzumab therapy. Trastuzumab benefit seemed independent of HER2/centromere 17 ratio and chromosome 17 copy number.